Edition:
United States

Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

97.09USD
8 Dec 2017
Change (% chg)

$0.47 (+0.49%)
Prev Close
$96.62
Open
$96.73
Day's High
$97.42
Day's Low
$96.30
Volume
240,941
Avg. Vol
322,279
52-wk High
$112.83
52-wk Low
$88.89

Chart for

About

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower... (more)

Overall

Beta: 0.60
Market Cap(Mil.): $13,233.31
Shares Outstanding(Mil.): 136.30
Dividend: 0.45
Yield (%): 1.85

Financials

  Industry Sector
P/E (TTM): -- 29.23 15.67
EPS (TTM): -- -- --
ROI: -- 7.53 34.62
ROE: -- 11.21 16.00

BRIEF-Quest Diagnostics provides update on impact of 2018 Medicare payment rates

* Quest Diagnostics provides update on impact of final 2018 Medicare payment rates for clinical laboratory tests

Nov 20 2017

Reimbursement cuts on lab tests pressure U.S. lab firm shares

A federal agency on Friday rolled out deep cuts to reimbursement rates for some lab tests under Medicare, a move that could save the government as much as $3 billion over five years, but hurt margins of U.S. laboratory companies.

Nov 20 2017

Reimbursement cuts on lab tests pressure US lab firm shares

Nov 20 A federal agency on Friday rolled out deep cuts to reimbursement rates for some lab tests under Medicare, a move that could save the government as much as $3 billion over five years, but hurt margins of U.S. laboratory companies.

Nov 20 2017

BRIEF-FDA approves Clinical Genomics, Quest Diagnostics Insure One

* Clinical Genomics and Quest Diagnostics announce FDA 510(k) clearance of Insure® One™

Nov 13 2017

BRIEF-Quest Diagnostics acquires certain assets of California Laboratory Associates

* Quest Diagnostics acquires California Laboratory Associates

Oct 30 2017

BRIEF-Advantage Capital Portfolio company Cleveland Heartlab acquired by Quest Diagnostics

* Advantage Capital Portfolio company Cleveland Heartlab, Inc acquired by Quest Diagnostics

Oct 19 2017

BRIEF-Quest Diagnostics reports Q3 diluted eps of $1.15

* Quest Diagnostics reports third quarter 2017 financial results, updates 2017 financial guidance and reaffirms long term outlook

Oct 19 2017

BRIEF-Fresenius Medical Care says divests Shiel Medical Laboratory to Quest Diagnostics

* Deal to generate modest book gain for Fresenius Medical Care

Sep 28 2017

BRIEF-Quest Diagnostics provides update on impact to 3rd quarter financial results from hurricanes

* Quest Diagnostics provides update on impact to third quarter financial results from hurricanes

Sep 27 2017

Fitch Affirms Quest Diagnostics at 'BBB'; Outlook Stable

(The following statement was released by the rating agency) NEW YORK, September 27 (Fitch) Fitch Ratings has affirmed the ratings of Quest Diagnostics Incorporated (NYSE: DGX) including the Issuer Default Rating (IDR) at 'BBB'. The Rating Outlook is Stable. A full list of ratings can be found at the end of the release. KEY RATING DRIVERS Leading Market Position: Quest is the largest independent player as measured by segment revenues in the relatively fragmented and highly competitive U.S. clinic

Sep 27 2017

Competitors

Earnings vs. Estimates